Nuclear Medicine
Nuclear medicine uses radioactive isotopes (radioisotopes or radionuclides) for both diagnosis and treatment of disease. Unlike conventional imaging, which reveals anatomy, nuclear medicine reveals function -- how organs work, where blood flows, how fast cells divide, and whether a tumor is metabolically active. It is one of the most direct applications of nuclear chemistry to human health.
Diagnostic Imaging: Tracing Metabolism
The principle of diagnostic nuclear medicine is elegant: attach a radioactive atom to a biologically active molecule, inject it into the patient, and detect the radiation it emits from outside the body. The radioactive compound (called a radiopharmaceutical or radiotracer) follows the same metabolic pathways as its non-radioactive counterpart, allowing physicians to image specific biochemical processes.
The ideal diagnostic radioisotope has several properties: it emits gamma rays (which can escape the body and be detected), has a short half-life (limiting patient radiation dose), produces no alpha or beta particles (which would damage tissue without contributing to the image), and can be chemically attached to biologically relevant molecules.
Technetium-99m: The Workhorse Isotope
Technetium-99m (Tc-99m) is the single most important isotope in diagnostic medicine, used in over 30 million procedures worldwide each year. The "m" stands for metastable -- it is a nuclear isomer that decays by emitting a single 140 keV gamma ray (ideal for imaging) with a 6.01-hour half-life (long enough for imaging, short enough to limit dose).
Tc-99m is obtained from molybdenum-99/technetium-99m generators (often called "moly cows"). Mo-99 (half-life 66 hours) is produced in nuclear reactors and shipped to hospitals, where it continuously decays to Tc-99m. The Tc-99m is eluted (washed out) from the generator with saline solution as needed, providing a fresh supply of the isotope on demand.
By attaching Tc-99m to different carrier molecules, physicians can image virtually any organ:
- Tc-99m-MDP (methylene diphosphonate): Bone scans detecting fractures, infections, and metastatic cancer
- Tc-99m-sestamibi: Cardiac perfusion imaging to diagnose coronary artery disease
- Tc-99m-MAA (macroaggregated albumin): Lung perfusion scans for pulmonary embolism
- Tc-99m-DTPA: Kidney function and filtration rate assessment
PET Scanning
Positron emission tomography (PET) uses isotopes that decay by positron emission. When the emitted positron encounters an electron (within about 1 mm), both particles annihilate, producing two 511 keV gamma rays traveling in exactly opposite directions. Detecting these coincident gamma rays allows precise 3D localization of the radiotracer.
Fluorine-18 fluorodeoxyglucose (F-18 FDG) is the most common PET tracer. FDG is a glucose analog that accumulates in cells with high metabolic activity. Cancer cells, which consume glucose at greatly elevated rates, light up brightly on FDG-PET scans. This makes PET invaluable for:
- Detecting and staging cancers
- Monitoring treatment response (a shrinking PET signal means the treatment is working)
- Distinguishing benign from malignant lesions
- Detecting Alzheimer's disease and evaluating seizure disorders
F-18 has a 110-minute half-life, requiring an on-site or nearby cyclotron for production. Other PET isotopes include carbon-11 (20 min), nitrogen-13 (10 min), oxygen-15 (2 min), and gallium-68 (68 min).
Radiation Therapy
While diagnostic nuclear medicine uses low doses of radiation to image the body, therapeutic nuclear medicine deliberately delivers high radiation doses to destroy diseased tissue, particularly cancer.
External beam radiation therapy (not strictly nuclear medicine, but related) uses high-energy photon or particle beams from outside the body. Cobalt-60 teletherapy units, once common, have been largely replaced by linear accelerators, though cobalt-60 remains important in developing countries.
Brachytherapy involves placing sealed radioactive sources directly into or adjacent to the tumor. Iodine-125 seeds permanently implanted in the prostate and cesium-137 or iridium-192 sources temporarily placed in the cervix or breast are common examples.
Systemic radionuclide therapy delivers radioactive drugs that selectively accumulate in target tissues:
- Iodine-131 for thyroid cancer and hyperthyroidism: The thyroid gland avidly absorbs iodine, concentrating the radioactive dose precisely where needed. This was the first targeted radionuclide therapy, introduced in the 1940s.
- Lutetium-177-DOTATATE (Lutathera) for neuroendocrine tumors: A somatostatin analog labeled with Lu-177 binds to receptors overexpressed on tumor cells.
- Radium-223 (Xofigo) for bone metastases from prostate cancer: Ra-223 is a calcium analog that localizes in bone, delivering targeted alpha radiation to metastatic deposits.
Radiation Dose in Medicine
Diagnostic nuclear medicine procedures deliver relatively low radiation doses. A typical Tc-99m bone scan delivers about 4-6 millisieverts (mSv), comparable to 1-2 years of natural background radiation. A whole-body FDG-PET scan delivers about 7-10 mSv. For comparison, a chest CT delivers about 7 mSv, and natural background radiation averages about 2.4 mSv per year worldwide. The diagnostic benefit of these procedures vastly outweighs the small radiation risk.